Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本


READING, UNITED KINGDOM
— Convatec Group Plc ("Convatec”), a leading global medical products and technologies company, welcomes the UK Government’s support for the wound care industry as part of its Life Sciences Sector Deal, and is pleased to set out its commitment to supporting the Government on the objectives it outlined. 

Through the Sector Deal, Convatec has been working with the Association of British HealthTech Industries, Health Care Providers and UK Academia, as part of a broader consortium across the healthcare sector, to identify ways to improve patient outcomes and maximise financial efficiency in wound care diagnosis and treatment. This includes the use of new digital clinical decision support tools to support health professionals and patients, helping to reduce variation in treatment and to ensure timely and appropriate care. 

Convatec’s contribution will be part of an investment of £10m over three years in UK based wound R&D and academia. Global Research & Development is focused in our facility in Deeside, Wales, and we will partner with NHS Health Providers and UK universities to pilot improvements in patient care. Going forward, the focus of Convatec’s investment will be in enhancing wound provision by supporting improved diagnostics and assessment, developing validated clinical pathways, ensuring greater consistency of care and providing accurate and timely data to help reduce overall management costs while improving clinical outcomes. 


Una Adderley, National Wound Care Strategy Programme Director, AHSN Network, said:  

“We are delighted that the Life Sciences Sector Deal 2 has included wound care as a focus.  Industry and innovation are important in the emerging National Wound Care Strategy Programme and we welcome this opportunity for closer collaborative working to improve care for patients with wounds.”


Simon Whitfield, Vice President & UK General Manager, Convatec, added:

“We are proud to be contributing to the Wound Care Sector Deal, which brings key stakeholders across the NHS, government and industry together to reduce variation in wound assessments and deliver better outcomes for patients and healthcare professionals. Our investment demonstrates Convatec’s support for the deal and illustrates its commitment to improving outcomes and value for patients across the UK.”

 

Enquiries

Media

Bobby Leach, VP Group Corporate Affairs, Convatec +44 (0)7776 662 787

Alastair Elwen, Finsbury +44 (0)207 251 3801


Analysts and Investors

John Crosse, VP Investor Relations, Convatec +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, Convatec +44 (0)7470 909 582

investorrelations@convatec.com

 

About Convatec

Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec’s products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and is included in the FTSE4Good ethical index.

 

Download PRESS RELEASE

PDF Download

 

Press Release

See all

5/13/2022

5/13/2022

Q1 Trading Update for the three months ended 31 March 2018

Q1 Trading Update for the three months ended 31 March 2018

Read more

5/13/2022

5/13/2022

Convatec announces changes within its U.S. Home Distribution Group

Convatec announces changes within its U.S. Home Distribution Group

Read more

5/13/2022

5/13/2022

Convatec announces 2018 Interim Results

Convatec announces 2018 Interim Results

Read more

5/13/2022

5/13/2022

03 July 2018 - Board Changes

03 July 2018 - Board Changes

Read more

5/13/2022

5/13/2022

Convatec Receives U.S. FDA 510(k) Clearance for Avelle™ Negative Pressure Wound Therapy System

Convatec Receives U.S. FDA 510(k) Clearance for Avelle™ Negative Pressure Wound Therapy System

Read more

5/13/2022

5/13/2022

Trading update for the three months ended 30 September 2018 and change in FY 2018 guidance

Trading update for the three months ended 30 September 2018 and change in FY 2018 guidance

Read more

5/13/2022

5/13/2022

Retirement of Chief Executive Officer and appointment of Rick Anderson as Chief Executive Officer (Interim)

Retirement of Chief Executive Officer and appointment of Rick Anderson as Chief Executive Officer (Interim)

Read more

5/13/2022

5/13/2022

US FDA 510(k) clearance for AQUACEL™ Ag Advantage

US FDA 510(k) clearance for AQUACEL™ Ag Advantage

Read more

5/13/2022

5/13/2022

Convatec Welcomes Wound Care Sector Deal

Convatec Welcomes Wound Care Sector Deal

Read more